The flexibility and scalability of our Olink® Explore platform can be utilized either to screen our entire library of 3072 assays, or in studies that focus on one or several of the eight Explore 384-plex panels that make up the Explore 3072 protein library.
These panels contain both established oncology-related protein biomarkers and exploratory biomarkers. The panel comprises human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell communication, cellular metabolic processes, apoptosis, cell proliferation/differentiation. Many of the assays also address proteins that are defined as relevant for cancer according to DisGenNet, including multiple markers associated with carcinogenesis, tumor progression, solid tumors, and recurrent tumors.
The Explore 384 Oncology and Oncology II panels offer simultaneous analysis of 384 protein biomarkers using just 1 µL of biological sample, and all assays are subject to Olink’s strict technical validation and Quality Control procedures.
The assays in different Explore 384 panels are divided into different probe pools, called blocks, with different sample dilution factors to ensure optimal read-out quality.
| The Oncology panel › | 1:1 | 1:10 | |
| The Oncology II panel › | 1:1 |
Note that relevant oncology biomarkers can also be placed in other Explore 384 panels for optimal readout quality.
Our technical validation of assays are performed in vitro using recombinant analytes. All technical validation data reported on the biomarker pages are based on these in vitro assays.
2947
Biomarker assays
~881 million
Protein data points generated
886
Publications listed on website